title: Comparison of the efficacy of prednisolone, montelukast, and omalizumab in an experimental allergic rhinitis model.
abstract: OBJECTIVE
  To compare the efficacy ofprednisolone, montelukast, and omalizumab in reducing allergic symptoms and inflammation at tissue level in an experimental allergic rhinitis model.
  
  
  METHODS
  Forty Sprague Dawley rats were randomized into 5 groups as naive (NS/NC), sensitized/challenged (S/C) by subcutaneous ovalbumin antigen injection, and montelukast-, prednisolone-, and omalizumab-treated groups. A nasal allergen challenge was performed every day from day 20 to day 26. The number of sneezes and nasal/eye rubbing movements, IL-4 and CysLT levels in serum, nasal and bronchoalveolar lavage fluids determined by ELISA, and histopathological findings of nasal mucosa, sinus, and lung tissues were compared.
  
  
  RESULTS
  All of the treatments significantly controlled the allergic symptoms of sneezing and nasal/eye rubbing (P < 0.05). IL-4 and CysLT levels on days 20 and 26 were significantly higher in the S/C group compared to the NS/NC group (P < 0.05). Montelukast significantly decreased serum and nasal IL-4 and CysLT levels (P < 0.05), prednisolone decreased nasal lavage IL-4 and CysLT levels (P < 0.05), and omalizumab lowered nasal lavage CysLT levels (P < 0.05).
  
  
  CONCLUSIONS
  Prednisolone, montelukast, and omalizumab were found to be effective in controlling the allergic symptoms of allergic rhinitis and upper/lower airway inflammation in an experimental allergic rhinitis model.
authors.affiliation: Department of Otorhinolaryngology - Head and Neck Surgery, Selçuk University, Konya, Turkey. bozkurtmetekaan@hotmail.com
authors.forename: Mete Kaan
authors.initials: MK
authors.lastname: Bozkurt
authors.forename: Baykal
authors.initials: B
authors.lastname: Tülek
authors.forename: Banu
authors.initials: B
authors.lastname: Bozkurt
authors.forename: Nalan
authors.initials: N
authors.lastname: Akyürek
authors.lastname: Öz Mehmet
authors.forename: Aysel
authors.initials: A
authors.lastname: Kiyici
mesh_terms: D000085:Acetates / Q000494:pharmacology*; D000818:Animals; D018926:Anti-Allergic Agents / Q000494:pharmacology*; D000888:Antibodies, Anti-Idiotypic / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D003521:Cyclopropanes; D004195:Disease Models, Animal; D008168:Lung / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D008407:Mast Cells / Q000187:drug effects / Q000469:parasitology; D009297:Nasal Mucosa / Q000166:cytology / Q000187:drug effects / Q000473:pathology; D000069444:Omalizumab; D011239:Prednisolone / Q000494:pharmacology*; D011804:Quinolines / Q000494:pharmacology*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D065631:Rhinitis, Allergic / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D012912:Sneezing / Q000187:drug effects; D013440:Sulfides
chemical_list: D000085:Acetates; D018926:Anti-Allergic Agents; D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D003521:Cyclopropanes; D011804:Quinolines; D013440:Sulfides; D000069444:Omalizumab; D011239:Prednisolone; C093875:montelukast